8,883 Shares in Charles River Laboratories International, Inc. $CRL Purchased by Evergreen Capital Management LLC

Key Points

• Evergreen Capital Management purchased 8,883 shares of Charles River Laboratories, valued at approximately $2.62 million, during the third quarter. Institutional investors collectively own 98.91% of the company.
• Several other funds increased their positions, while insiders sold 118,169 shares worth $35.2 million over the past three months; insiders retain a 1.30% ownership stake.
• Analysts maintain a consensus “Moderate Buy” rating with an average price target of $302.33. Charles River exceeded quarterly earnings expectations, reporting $3.02 in EPS versus the $2.77 estimate, despite a 2.7% year-over-year revenue decline.

Evergreen Capital Management LLC acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 8,883 shares of the medical research company's stock, valued at approximately $2,621,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Sterling Capital Management LLC raised its stake in Charles River Laboratories International by 350.3% in the 3rd quarter. Sterling Capital Management LLC now owns 6,642 shares of the medical research company's stock valued at $1,959,000 after acquiring an additional 5,167 shares during the period. Yousif Capital Management LLC lifted its holdings in Charles River Laboratories International by 721.8% during the 3rd quarter. Yousif Capital Management LLC now owns 43,367 shares of the medical research company's stock valued at $12,794,000 after purchasing an additional 38,090 shares during the last quarter. Compass Wealth Management LLC bought a new position in Charles River Laboratories International during the third quarter worth $69,000. Cardinal Capital Management boosted its position in Charles River Laboratories International by 4.9% during the third quarter. Cardinal Capital Management now owns 11,756 shares of the medical research company's stock worth $3,468,000 after purchasing an additional 550 shares during the period. Finally, Crossmark Global Holdings Inc. boosted its position in Charles River Laboratories International by 197.3% during the third quarter. Crossmark Global Holdings Inc. now owns 12,773 shares of the medical research company's stock worth $3,768,000 after purchasing an additional 8,476 shares during the period. 98.91% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CAO Michael Knell sold 6,645 shares of the firm's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $260.38, for a total transaction of $1,730,225.10. Following the transaction, the chief accounting officer directly owned 11,852 shares of the company's stock, valued at approximately $3,086,023.76. This trade represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Shannon Parisotto sold 5,046 shares of Charles River Laboratories International stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $263.00, for a total transaction of $1,327,098.00. Following the completion of the sale, the executive vice president owned 4,807 shares of the company's stock, valued at $1,264,241. This trade represents a 51.21% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 118,169 shares of company stock valued at $35,191,216 in the last three months. Insiders own 1.30% of the company's stock.

Wall Street Analysts Forecast Growth

CRL has been the topic of several research reports. Barclays upped their price objective on shares of Charles River Laboratories International from $300.00 to $330.00 and gave the company an "overweight" rating in a report on Friday, September 25th. CLSA cut shares of Charles River Laboratories International from an "outperform" rating to a "hold" rating and set a $219.00 target price for the company. in a research note on Monday, July 20th. JPMorgan Chase & Co. upgraded shares of Charles River Laboratories International from a "neutral" rating to an "overweight" rating and raised their target price for the stock from $180.00 to $310.00 in a research note on Thursday, August 6th. Mizuho lifted their target price on shares of Charles River Laboratories International from $264.00 to $295.00 and gave the stock a "neutral" rating in a report on Friday, September 25th. Finally, Robert W. Baird upped their price target on shares of Charles River Laboratories International from $291.00 to $334.00 and gave the company an "outperform" rating in a research note on Friday, September 25th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Charles River Laboratories International presently has a consensus rating of "Moderate Buy" and an average target price of $302.33.

Charles River Laboratories International Stock Performance

Shares of NYSE CRL opened at $356.76 on Tuesday. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. The firm has a market cap of $17.03 billion, a price-to-earnings ratio of -73.56, a P/E/G ratio of 3.23 and a beta of 1.40. The stock's fifty day moving average price is $295.70 and its two-hundred day moving average price is $219.36. Charles River Laboratories International, Inc. has a one year low of $146.20 and a one year high of $357.77.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.25. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The company's revenue was down 2.7% on a year-over-year basis. During the same quarter last year, the firm earned $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, equities analysts forecast that Charles River Laboratories International, Inc. will post 11.38 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.